The doppel (Dpl) protein influences in vitro migration capability in astrocytoma-derived cells

Alberto Azzalin, Elena Sbalchiero, Giulia Barbieri, Silvia Palumbo, Cristina Muzzini and Sergio Comincini

Dipartimento di Genetica e Microbiologia, Università di Pavia, Pavia, Italy

Abstract. Doppel (Dpl) protein is the paralogue of the cellular prion (PrP\textsuperscript{C}) protein. In humans, Dpl is expressed almost exclusively in testis where it is involved in spermatogenesis. Recently, the protein has been described to be ectopically expressed in astrocytomas and its potential association to the brain tumor malignancy progression has been advanced. In this study, we aimed to investigate in vitro the potential involvement of Dpl in the tumor cell migration: to this purpose, Dpl expression was reduced in the IPDDC-A2 astrocytoma-derived cell line, by means of antisense and siRNA approaches; migration rates were then evaluated by means of a scratch wound healing assay. As a result, the cellular migration was sensibly reduced after Dpl silencing. Following a complementary approach, in HeLa cells, showing very low endogenous Dpl expression, the protein expression was induced by transfection and stabilization of an eukaryotic expression vector containing the doppel gene coding sequence. These stably Dpl-overexpressing cells revealed a significant increase in the migration rate, compared to untreated and control cells. In addition, Dpl-forced expression induced substantial changes in the cell morphology. Of note, in these cells, viability examination by means of tetrazolium-based assay did not reveal differences in the proliferation; on the contrary, a variation in density-dependent growth, leading to an increase of cell contact inhibition was highlighted. These results, in conclusion, might suggest a potential and functional role for Dpl in tumor cells migratory and morphological behaviours and address to future gene-targeted therapeutic interventions.

Keywords: Prion-like proteins, glial tumor, IPDDC-A2, HeLa, siRNA, antisense oligonucleotide, gene-silencing, migration scratch assay

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| CNS          | Central nervous system, |
| D-MEM        | Dulbecco’s modified eagle’s medium, |
| GPI          | Glycosyl-phosphatidyl-inositol, |
| IRES         | Internal ribosome entry site, |
| MTS          | 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, |
| NMR          | Nuclear magnetic resonance, |
| S-ODN        | Phosphothioate-oligonucleotide, |
| PBS          | Phosphate buffered saline, |
| SD           | Standard deviation, |

SDS-PAGE: Sodium dodecyl sulphate-polyacrylamide gel electrophoresis, 
siRNA: Short interfering RNA, 
WHO: World health organization.

1. Introduction

The majority of malignant brain tumors is derived from glial cells and most of them display an astrocytic component, but the high degree of heterogeneity often makes it difficult to determine the cell of origin [23,24]. Four malignancy grades are accepted by the WHO, from grade I, the biologically least aggressive, to the grade IV tumors (glioblastoma), the most aggressive [30]. Despite advances in clinical and molecular fields, high grade astrocytomas remain fatal, particularly because of striking rates of de novo and acquired resistance to therapeutic intervention [7]. Up to date, no therapy has been able to give tangi-
ble improvements in the prognosis and the survival of patients with this pathology is often less than one year [44,46]. Malignant astrocytomas, like most aggressive cancers, present aberrant proliferation, diminished apoptosis, escaping from both growth control and immuno-regulation [23]. Moreover, these tumors exhibit a characteristic ability to infiltrate healthy brain tissue and form satellite tumors. To this regard, many genes have been identified to be associated with astrocytic tumors migration [15,40]. This migration capacity makes these tumors exceedingly difficult to treat and even after resection, invasive cells can give rise to tumors within centimeters of the resection site [15].

In the recent past, the first prion-like protein gene, doppel (PRND), was described in rodents, cattle, sheep, goat and human [28,36,38,51,53]. In 2004, we first reported an altered expression of this gene in brain tumors, and we hypothesized that doppel might be considered as an astrocytic tumors progression marker [10]. Doppel gene product, Dpl, is a paralogue of the cellular prion protein (PrPc), the main causative agent of spongiform encephalopathies, but it seems not be involved in these diseases [52]. Human Dpl protein is composed of 126 aminoacids, GPI-anchored to the cytoplasmic membrane, highly glycosylated and NMR analysis confirmed a carboxy-terminal domain composed of three α-helices and two β-sheets [31]. Dpl, differently from PrPc that is widely expressed in different tissues, is described only in adult testis where it is involved in spermatogenesis and fertilization capability [6,33,41]. As we recently documented, Dpl is ectopically expressed in brain tumors; additionally, PRND mRNA expression was associated with the glial tumor malignant transformation [11]. Furthermore, in these tumors, the transcript showed a nuclear retention and the protein product was subjected to an unusual glycosylation; finally, Dpl failed to be GPI-anchored at the astrocytic tumor cellular membrane and it was mainly localized in the cellular cytoplasm [8].

In this work, an in vitro functional analysis was performed to clarify the role of the doppel gene product in regulating cell migration in human brain tumors.

2. Materials and methods

2.1. Cell lines and culture reagents

Human astrocytoma-derived IPDDC-A2 and cervical carcinoma HeLa cell lines (ECACC, Salisbury, UK) were employed. Cells were maintained at 37°C, 5% CO2 in D-MEM supplied with 10% fetal bovine serum, 1% L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cell culture media and supplements were provided by Invitrogen (Carlsbad, CA, USA). For transfectants selection, puromycin (Sigma-Aldrich, St. Louis, MO, USA) was employed.

2.2. siRNA, antisense DNA oligonucleotides and treatments

Three PRND-specific siRNA molecules were purchased from Ambion (Austin, TX, USA). Their sequences were: Silencer® siRNA ID# 133939-sense 5'-GCA AUC GCAG UUG CAC CAA ATT-3' and 133940-antisense 5'-GUG UGC ACU UGG CAG AUU CAG CTG-3', ID# 133940-sense 5'-GCC UUA UGA AGG CCA UCA UTC-3' and 133940-antisense 5'-AUG AUC GCC UUC AUU AGG CTC G-3', ID# 133941-sense 5'-CCA CUC UAA UAG CUA AAA ATT-3' and 133941-antisense 5'-UUU UUU UUA GCU AAG GUG Ctg-3'. A GAPDH-specific Silencer® siRNA was employed as control (ID# 4624).

Two antisense DNA oligonucleotides (ODN), fully phosphorothioated and HPLC-purified, were provide by Sigma®-Genosys. PRND-specific antisense S-ODN sequence was 5'-ATG AGG AGG CAC CTG AGC TG-3' and GAPDH-specific antisense S-ODN sequence was 5'-CCG ACC TTC ACC TTC CCC AT-3', both complementary to the first twenty nucleotides of their respectively gene coding sequences.

Transfection reactions were carried out using Lipofectamine™ 2000 reagent (Invitrogen) on a cells monolayer of about 70% confluence previously plated on 30 mm Petri dishes (Corning, New York, NY, USA) and, after respectively 18 and 24 h, migration assay and western blot analysis were performed. Briefly, the PRND-specific siRNAs were co-transfected, each one at the final concentration of 0.10 μM, in presence of 5.0 μl of transfection reagent; antisense S-ODNs were transfected at the final concentration of 1.57 μM with 2.5 μl of liposome reagent. Antibiotics-free medium was employed.

2.3. Plasmids construction

For overexpression experiments, pIRESpuro3 plasmid (Clontech Laboratories Inc., Palo Alto, CA, USA) was employed. The human doppel protein coding sequence was amplified from genomic DNA (Clontech Laboratories Inc.) using the following primers: Dpl(EcoRI)-U, 5'-CCG GAA TTC ATG AGG AGG CAC CTG AGC TG-3' and Dpl(NotI)-L, 5'-TGC GGC
CGC TTA TTT CAC CAT GAG CCA GAT CA-3;
the PCR product was then EcoRI/NorI-cloned into the plasmid, thus originating the pIRESpuro3-PRND construct. As control, the pIRESpuro3-PRNP construct was prepared as follow: the human prion protein coding sequence was amplified from genomic DNA (Clontech Laboratories Inc.) employing the following primers: PrP(EcoRI)-U, 5′-CCG GAA TTC ATG GCG AAC CTT GGC TGC-3′ and PrP(NorI)-L, 5′-ATT TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC GGC CGC TTA TCA TCC CAC TAT CAG GAA TGC G
antibiotics-free medium (except 1 µg/ml of puromycin), the scratch assay was performed as previously described.

Morphology analysis and photographs were made using the inverted microscope Nikon Eclipse TS100 (Nikon, Tokyo, Japan).

2.7. Cell viability and cell growth assays

To test the cellular viability, an MTS-based assay, the “CellTiter 96® Aqueous One Solution Cell Proliferation Assay” (Promega, Madison, WI, USA) was employed. Cells were plated into 96-wells flat-bottom plate in triplicate at a density of 10⁴ cells per well. First readouts were measured 24 h after plating and then at intervals of 24 h, following the manufacturer’s instructions. Readouts were measures with a microplate reader (Titertek Multiskan, Huntsville, AL, USA) at 492 nm wavelength.

Growth curves were made employing a 96-wells plate: similarly, stably Dpl-expressing HeLa cells were plated at a density of 10⁴ per well in triplicates. The cells were incubated up to 8 days: at intervals of 24 h, cells were trypsinized and counted by a hemocytometer.

2.8. Software employed and statistical analysis

The software employed for densitometric analysis was the GelixOne version 1.2.1 (Biostep GmbH, Jahnsdorf, Germany). Statistical analysis and graphs design were performed with Office Excel (Microsoft, Redmond, WA, USA); figures were processed with Illustrator® 10.0 (Adobe Systems Inc., San Jose, CA, USA). Data are expressed as mean ± SD of two independent experiments. The results were analyzed using the Student’s t test; p value inferior to 0.05 was considered significant.

3. Results

Astrocytoma-derived cell line IPDDC-A2 (previously characterized for doppel expression in [8,14]) was transiently transfected with PRND-specific siRNA and antisense S-ODN molecules at a final concentration of 0.30 and 1.57 µM, respectively; immunoblotting analysis, carried out 24 h after transfection, showed a decreased Dpl protein expression of the previously described Dpl isoforms (Fig. 1(a)). Specifically, a more defined Dpl knockdown effect at this interval was obtained after S-ODN-treatment. A densitometrical analysis of the 30 kDa Dpl electrophoretic band, widely conserved in protein extracts from different tumor cells, in S-ODN- and siRNA-treated samples reported, respectively, an intensity of 35% and 49%, compared to the untreated sample (Fig. 1(a)).

To verify whether the doppel expression disruption was able to influence cell migration in vitro, we performed a scratch assay in IPDDC-A2 cells subjected or not to a PRND silencing. Since a strong reduction of Dpl was observed at 24 h after transfection with siRNA and S-ODN molecules, experiments addressing cellular migratory capacity were carried out accordingly. As shown in Fig. 1(b), both silencing techniques induced a sensitive decrease in the cell motility. As a negative control, validated GAPDH-specific siRNA and GAPDH-antisense S-ODN molecules were assayed: these interfering treatments did not influence cells migration ability. In particular, siRNA treatment showed the phenotypic effect earlier than S-ODN treatment, as shown in Fig. 1(c). The average migration rate varied from about 60 µm/h, in untreated and GAPDH-transfected cells, to approximately 40 µm/h, in Dpl-silenced cells. Finally, Fig. 1(b) shows some snapshots of the cells treated with the Dpl-silencing molecules respect to the not treated cells.

To extend the Dpl specific effect on the migrating phenotype, a different tumor cell line was assayed. HeLa cells, that showed a very low Dpl protein expression as reported in Fig. 2(a), have been stably transfected with the eukaryotic expression vector pIRE-Spuro3 (Clontech Laboratories Inc.) containing the PRND gene coding sequence. As shown in Fig. 2(a), Dpl protein displayed a heterodisperse intense band respects to the cell line stably selected for pIRESpuro3 plasmid alone and to the untreated cells. In addition, the PRNP gene coding sequence was cloned into the pIRESpuro3 plasmid and stably transfected HeLa cells overexpressing PrPc protein, as shown in Fig. 2(a), were then assayed for migration capability. As reported in Fig. 2(c), the graph indicated an increase migration rate for Dpl-expressing cells (about 17 µm/h), while untreated cells, empty plasmid-selected cells and PrPC-expressing cells exhibited a similar migration capability, significantly lower than Dpl-expressing cells (7 µm/h). Interestingly, stably expressing PrPC and Dpl proteins cells, showed a migration rate similar to the Dpl transfectants (Fig. 2(c)). Finally, Fig. 2(b) showed photographs of Dpl-expressing and untreated cells, 24 h after performing the scratch.

Furthermore, stable Dpl transfectants were subjected to a treatment with the PRND-specific S-ODN
molecules: a partial rescue of the migration rate of these cells was observed, respect to the untreated and to the GAPDH-specific S-ODN treated cells (Fig. 3).

Of note, average migration rate of untreated IPDDC-A2 cells on the Petri plastic support was much more higher than untreated HeLa, respectively 43 ± 0.1 µm/h and 7 ± 0.1 µm/h.

Dpl stably expressing HeLa cells were analyzed for cellular parameters such as viability, growth and morphology. As reported in Fig. 4(a), the viability assay...
Fig. 2. Stably selected HeLa cells and migratory behaviour analysis. (a) Western blot analysis of HeLa cells overexpressing Dpl (pIRESpuro3-PRND) and PrP^C (pIRESpuro3-PRNP) respects to the empty-vector transfectants (pIRESpuro3) and the not-transfected (NT HeLa) controls. (b) The snapshots of the cell monolayer scratches indicate the increased migration rate for the overexpressing HeLa (pIRESpuro3-PRND) respects to the untreated cells (NT HeLa), observed at 24 h after scratch. Scale bars are reported (50 µm). (c) The migration rate curves of the stably transfected HeLa cells expressing Dpl (pIRESpuro3-PRND) or co-expressing both Dpl and PrP^C (pIRESpuro3-PRND + pIRESpuro3-PRNP) proteins show a higher value respect to, respectively, untreated (NT HeLa), empty vector transfected (pIRESpuro3) and PrP^C expressing cells (pIRESpuro3-PRNP). Statistical analysis was performed by Student’s t test (p < 0.05).

carried out with a tetrazolium-based method, showed similar curves for all the samples (correlation coefficients average $r = 0.99 \pm 0.012$), within the first 72 h. Figure 4(b) reported HeLa growth curves that were similar for untreated, for empty vector-transfectants and for stably expressing PrP^C cells. On the contrary, Dpl overexpressing cells showed a modified growth curve, particularly at the plateau phase, measurably lower than expected. Cells expressing both Dpl and PrP^C proteins showed a growth curve similar to the control. With regard to morphological aspects reported in Fig. 4(c), Dpl- and Dpl/PrP^C-expressing cells showed relevant alterations in the cellular shape: the typical squared shape of HeLa cells, resulting after empty vector and PRNP transfection, changed towards a lengthened and flattened forms in Dpl- and Dpl/PrP^C-expressing cells. In particular, the average length of Dpl-expressing cells varied from 75 to 175 µm com-
Fig. 3. Migration rate rescue in Dpl-expressing HeLa cells. The PRND-specific S-ODN treatment of the stably Dpl-expressing HeLa cells reduced their migration capability respects to untreated (NT HeLa) and to GAPDH-specific S-ODN treated cells (ODN-GAPDH). Statistical analysis was performed by Student’s t test (p < 0.05).

pared to the controls (50–75 µm length); moreover, the nuclei underwent a significant dimension increase from about 25–30 µm to 37.5–40 µm in diameter, respectively.

4. Discussion

Astrocytomas are the most common CNS neoplasms; the accepted tumor grading is composed by four classes (WHO I–IV) according to the histological characteristics, but many efforts are performed, at the molecular level, to improve this classification [37]. We have recently proposed a potential novel marker, the doppel gene, PRND, the expression of which correlates with the astrocytoma malignancy [10,11]. PRND encodes for the Dpl protein, the first discovered paralogue of the cellular prion protein, PrPC, the agent involved in spongiform encephalopathy diseases [38,43]. Dpl is expressed almost entirely in adult testis where it plays a role in spermatogenesis and in male fertilization but, as we described, it was ectopically and consistently up-regulated in brain tumors [6,9,41]. In this pathological context, some biological variations occurred respects to the physiological conditions: its transcript was retained in the nucleus, underwent an alternative splicing event and might be subjected to post-transcriptional modifications similarly to other genes involved in glioma progression [29]; moreover, the gene product failed to be GPI-anchored to the cytoplasmic membrane and it finally localized in the cytoplasm, undergoing a heavy and unexpected glycosylation [8].

Up to now, our investigations about doppel in the tumor context failed to trace a hypothetical functional role [1,2]. In this work, we analyzed the involvement of Dpl into one of the typical hallmarks of cancer, cell migration. Cells movement is a complex mechanism that is subjected to a rigid control by several genes during various stages of embryonic and adult developmental processes; during carcinogenesis, the motile behaviour reappears without usual cellular controls and this causes tumor cells spreading throughout the healthy tissue [45]; moreover, cancer cells motility plays a primary role in tumor invasion and metastasis formation [57]. In particular, in astrocytomas, infiltration ability of tumor cells constitutes one of the main causes of the unfortunate prognosis for these malignancies and it explains the intensive efforts in aiming the development of novel therapies [27,44]. Several key proteins are described as effectors of migratory ability of astrocytoma cells and several analysis of the transcriptomes are carried out to discovery novel targets [15,16,21,39].

The in vitro cellular assay to investigate the role of Dpl in tumor cells migration was performed in an astrocytoma established cell line, i.e. IPDDC-A2, showing detectable levels of Dpl expression, and in HeLa cells, as a Dpl-low expressing cell system. Among several available astrocytoma-derived cell lines (Hu-2 [3], D384-MG [4], U-87 MG and U-373 MG [42]), IPDDC-A2 was employed for the more substantial Dpl expression level and for its highest viability and transfection efficiency of nucleic acids. The migration behaviour was analyzed, respectively, in Dpl-silenced IPDDC-A2 and in stable Dpl-expressing HeLa cells, using an in vitro scratch wound healing assay on a cell monolayer, a widely used method to test the migration efficiency of a cell line, as reviewed in [54]. Dpl silencing was performed using two complementary approaches, namely antisense oligonucleotides-based technology and siRNA. These approaches share some similarities in the length molecules and in inducing target degradation after a complementary mRNA hybridization. On the other side, while siRNA adopt a specific cellular machinery (i.e. the RNA induced silencing complex, RISC), antisense technology is mainly based on RNA–DNA duplexes, that obstruct the ribosome processing and induce RNase H-mediated degradation. However, impor-
Fig. 4. Growth, viability assays and morphology evaluations. (a) An MTS-based assay was performed to evaluate the cellular viability. Absorbance readouts at 492 nm, evaluated at 24, 48, 72, and 96 h time intervals, revealed a similar behaviour among overexpressing Dpl (pIRE-Spuro3-PRND), PrPC (pIRE-Spuro3-PRNP), both Dpl and PrPC (pIRE-Spuro3-PRND + pIRE-Spuro3-PRNP), empty vector transfectants (pIRE-Spuro3) and untreated cells (NT HeLa). (b) The growth curves of the cells (evaluated for a 192 h time course) were analyzed; Dpl overexpressing cells show a lower plateau threshold compared to other cells. (c) Morphological analysis of HeLa cells, at 10×, 20×, and 40× magnifications respectively, show relevant alterations in the cellular shape: the typical squared shape of HeLa cells changes towards a lengthened forms in Dpl- and Dpl/PrPC-expressing cells. Scale bars are reported (30 µm).

Fig. 4. Growth, viability assays and morphology evaluations. (a) An MTS-based assay was performed to evaluate the cellular viability. Absorbance readouts at 492 nm, evaluated at 24, 48, 72, and 96 h time intervals, revealed a similar behaviour among overexpressing Dpl (pIRE-Spuro3-PRND), PrPC (pIRE-Spuro3-PRNP), both Dpl and PrPC (pIRE-Spuro3-PRND + pIRE-Spuro3-PRNP), empty vector transfectants (pIRE-Spuro3) and untreated cells (NT HeLa). (b) The growth curves of the cells (evaluated for a 192 h time course) were analyzed; Dpl overexpressing cells show a lower plateau threshold compared to other cells. (c) Morphological analysis of HeLa cells, at 10×, 20×, and 40× magnifications respectively, show relevant alterations in the cellular shape: the typical squared shape of HeLa cells changes towards a lengthened forms in Dpl- and Dpl/PrPC-expressing cells. Scale bars are reported (30 µm).

Importantly, the in vitro or in vivo efficacy of antisense versus siRNA technology is not theoretically predictable [12]. For the antisense technology, a fully phosphothioate DNA oligonucleotide (S-ODN), widely employed in cancer research [25, 35, 50], was designed against the first twenty nucleotides of the PRND coding sequence. As reported, after transfection, an earlier phenotypic effect on the cell migration after siRNA treatment respect to S-ODNs was detected; however, as immunoblotting revealed, S-ODN molecules showed a more efficient silencing on doppel protein expression than pre-designed siRNA molecules at twenty-four hours after transfection. This phenomenon might be related to an enhanced cellular stability of S-ODN compared to siRNA molecules and, conversely, to an earlier and more transient effect of PRND-specific siRNA on cellular migration [49].

To better evaluate the contribution of the doppel gene product in tumor cell migration, stably expressing Dpl HeLa cells were produced. HeLa cells, that showed a very low endogenous Dpl expression as revealed by real time PCR analysis (data not shown) and western blotting analysis (this work), were transfected and stabilized with the eukaryotic expression plasmid pIRE-Spuro3 containing the PRND coding sequence. Transfected HeLa cells were selected for the stable overexpression of Dpl and the scratch wound healing assay was carried out. Western blot analysis re-
revealed a Dpl diffuse band of about 30–45 kDa, similar to that generally observed in the normal human testis tissue [41]. The migration rate of the Dpl-expressing HeLa cells was sensibly increased, more than two-fold higher, respects to the untreated cells and to the cells stably selected for the empty vector alone, proving that the effect of Dpl on migration capability of the cells was cell-type specific and due to the expression of Dpl. In addition, we treated these transfectants with the PRND-decoy ODNs previously tested with IPDDC-A2 cells instead of siRNA whose targets are located outside the PRND coding sequence and this make the mRNA transcript derived from the pIRESpuro3-PRND construct an “off-target” for our siRNA molecules: the treatment partially restored the migration rate similar to the untreated HeLa, while GAPDH-specific S-ODN did not affect this behaviour. Furthermore, we transfected and stably selected HeLa cells with the plasmid containing cellular prion protein coding gene sequence and, as we reported, cells overexpressing PrPC did not show variations in migratory behaviour neither in morphology. The rationale of using this construct was because PrPC and Dpl are homologue proteins that display a strong structural similarity [34]. Interestingly, when we examined the HeLa cells stably selected for both the plasmids containing PRND and PRNP coding sequences, the migration rate became similar to the Dpl-expressing cells. To this regard, our data showed that Dpl and PrPc might exhibit different functions, following the hypothesis that two paralogue genes, after the duplication from their ancestor, are subjected to mutations that originate two functionally different genes with dissimilar expression patterns [32]. Furthermore, under our experimental conditions that consider cellular migratory behaviour, Dpl and PrPc did not display any antagonizing role; differently, as previously described, in prion knock-out animal models and cell lines, Dpl neurotoxic effects were counteracted by PRNP transgene reintroduction [5,56]. However, in our cellular system, i.e. HeLa cells, the potentially toxic effect determined by the overexpression of doppel was not observed.

To discern the increased migration in Dpl-silenced cells from differences in viability rates, proliferation assays were performed in HeLa cells in a ninety-six growing time interval. Untreated HeLa and Dpl-stable expressing cells had a similar growing behaviour with, however, a significant difference of cell density in Dpl-overexpressing ones: these, differently from HeLa or other tumor cells, failed to reach a complete plate growth density, probably because of an augmented contact inhibition. This phenomenon might be also sustained by the documented differences in cell morphology after Dpl-expression stabilization, possibly explained by the interfering with unknown networks of genes involved in density-dependent cell growth [17, 18,20,22]. An inverted correlation between migration and growth rates, the “go or grow” dichotomy, was already described in tumor cells; however, the molecular and cellular mechanisms involved in these mutually exclusive phenotypes, are up to now not completely elucidated [18,19]. In the case of human astrocytomas, it might be hypothesized that Dpl is expressed mostly in the highly migratory cells of the external edge of the tumor area (work in progress). It is possible to hypothesized that doppel influence cell migration by means of its physiological cellular membrane localization that might be involved in cell-to-cell contacts; however, our knowledge about doppel localization in a tumor scenario could not sustain this speculation since we reported a cytoplasmic ectopic localization of the protein in astrocytoma [8,47]. An additional possibility is that doppel could take part to an up to now unknown signaling network that might influence migration. To this regard, we recently documented RACK1 (Receptor for Activated C-Kinase) as a Dpl interacting protein [2]. RACK1 is an adaptor protein that regulates signaling via Src- and PKC (protein kinase C)-dependent pathways and in particular it has been described to modulate the integrin-mediated cellular adhesion and migration [13,26,48].

Furthermore, as we reported, a forced-Dpl expression induced an irreversible morphological change in HeLa cells. This phenotype was Dpl-specific, since prion and empty expression vector did not induce differences in their cellular shape. Variations in cell motility is often associated with morphological changes and differences in actin expression [55]: to this regard, however, HeLa-treated cells did not exhibit differences in actin expression (data not shown), suggesting that other cyto-architectural proteins might be involved. Finally, neither siRNA nor ODNs treatment of IPDDC-A2 cells showed morphological changes, probably due the transient mechanism of action of these molecules.

In summary, our study highlighted for the first time a functional role of the doppel gene product in inducing differences in astrocytic tumor cell migration and morphology, suggesting a potential antisense therapy against this target protein with the aim of interfering with the described phenotypes.
Acknowledgements

This study was supported by a grant from the Italian MIUR, “Progetti di Ricerca di Rilevante Interesse Nazionale (2005)”; A.A. is granted by Fondo Sociale Europeo (F.S.E.); the authors are grateful to: Prof. Valentini (University of Pavia) for providing the anti-human Dpl antibody; Prof. Ferretti and Prof. Ranzani (University of Pavia) for providing cell culture facilities; Prof. Giulotto (University of Pavia) for providing eukaryotic expression vector.

References

[1] A. Azzalin, I. Del Vecchio, L.R. Chiarelli et al., Absence of interaction between doppel and GFAP, Grb2, PrP proteins in human astrocytic cells, Anticancer Research 25 (2005), 4369–4374.
[2] A. Azzalin, I. Del Vecchio, L. Ferretti et al., The prion-like protein doppel (Dpl) interacts with the human receptor for activated C-kinase 1 (RACK1) protein, Anticancer Research 26 (2006), 4539–4548.
[3] G. Baccioni, N. Gibelli, C. Zibera et al., Establishment and characterization of two cell lines derived from human glioblastoma multiforme, Anticancer Research 12 (1992), 853–861.
[4] A.J. Balmfort, S.G. Ball, R.I. Freshney et al., D-1 dopaminergic and β-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM, Journal of Neurochemistry 47 (1986), 715–719.
[5] A. Behrens and A. Aguzzi, Small is not beautiful: antagonizing functions for the prion protein PrP(C) and its homologue Dpl, Trends in Neuroscience 25 (2002), 150–154.
[6] A. Behrens, S. Brandner, N. Genoud et al., Absence of the prion protein homologue doppel causes male sterility, EMBO Journal 21 (2002), 3652–3658.
[7] V.P. Collins, Mechanisms of disease: genetic predictors of response to treatment in brain tumors, Nature Clinical Practice Oncology 4 (2006), 362–374.
[8] S. Cominini, L.R. Chiarelli, P. Zelini et al., Nuclear mRNA retention and aberrant doppel protein expression in human astrocytic tumor cells, Oncology Reports 16 (2006), 1325–1332.
[9] S. Cominini, I. Del Vecchio and A. Azzalin, The doppel gene biology: a scientific journey from brain to testis, and return, Central European Journal of Biology 1 (2006), 494–505.
[10] S. Cominini, A. Facoetti, I. Del Vecchio et al., Differential expression of the prion-like protein doppel gene (PRND) in astrocytomas: a new molecular marker potentially involved in tumor progression, Anticancer Research 24 (2004), 1507–1517.
[11] S. Cominini, V. Ferrara, A. Arias et al., Diagnostic value of PRND gene expression profiles in astrocytomas: relationship to tumor grades of malignancy, Oncology Reports 17 (2007), 989–996.
[12] D.R. Corey, RNA learns from antisense, Nature Chemical Biology 3 (2007), 8–11.
[13] E.A. Cox, D. Bennin, A.T. Doan et al., RACK1 regulates integrin-mediated adhesion, protrusion, and chemotactic cell migration via its Src-binding site, Molecular Biology of the Cell 14 (2003), 658–669.
[14] I. Del Vecchio, A. Azzalin, E. Guidi et al., Functional mapping of the bovine doppel gene promoter region, Gene 356 (2005), 101–108.
[15] T. Demuth and M.E. Berens, Molecular mechanisms of glioma cell migration and invasion, Journal of Neuro-Oncology 70 (2004), 217–228.
[16] T. Demuth, J.L. Rennet, D.B. Hoelzinger et al., Glioma cells on the run – the migratory transcriptome of 10 human glioma cell lines, BMC Genomics 29 (2008), 9–54.
[17] F. Fagotto and B.M. Gumbiner, Cell contact-dependent signaling, Developmental Biology 180 (1996), 445–454.
[18] A. Giese, R. Bjerkvig, M.E. Berens et al., Cost of migration: invasion of malignant gliomas and implications for treatment, Journal of Clinical Oncology 21 (2003), 1624–1636.
[19] A. Giese, M.A. Loo, N. Tran et al., Dichotomy of astrocytoma migration and proliferation, International Journal of Cancer 67 (1996), 275–282.
[20] B.M. Gumbiner, Cell adhesion: the molecular basis of tissue architecture and morphogenesis, Cell 84 (1996), 345–357.
[21] D.B. Hoelzinger, L. Mariani, J. Weis et al., Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets, Neoplasia 7 (2005), 7–16.
[22] R.O. Hynes, Cell adhesion: old and new questions, Trends in Genetics 15 (1999), M33–M37.
[23] K. Ichimura, H. Ohgaki, P. Kleihues et al., Molecular pathogenesis of astrocytotic tumors, Journal of Neuro-Oncology 70 (2004), 137–160.
[24] K.R. Jessen, Glial cells, International Journal of Biochemistry & Cell Biology 36 (2004), 1861–1867.
[25] A. Kalota, Progress in the development of nucleic acid therapeutics for cancer, Cancer Biology & Therapy 3 (2004), 4–12.
[26] P.A. Kiely, D. O’Gorman, K. Luong et al., Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and β integrin to promote cell migration, Molecular and Cellular Biology 26 (2006), 4041–4051.
[27] F. Lefranc, J. Brotchi and R. Kiss, Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis, Journal of Clinical Oncology 23 (2006), 2411–2422.
[28] A. Li, S. Sakaguchi, R. Atarashi et al., Identification of a novel gene encoding a PrP-like protein expressed as chimeric transcripts fused to PrP exon 1/2 in ataxic mouse line with a disrupted PrP gene, Cellular and Molecular Neurobiology 20 (2000), 553–567.
[29] I. Lopez de Silanes, M.P. Quesada and M. Esteller, Aberrant regulation of messenger RNA 3′-untranslated region in human cancer, Cellular Oncology 29 (2007), 1–17.
[30] D.N. Louis, H. Ohgaki, D.O. Wiestler et al., The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathologica 114 (2007), 97–109.
[31] T. Lührs, R. Riek, P. Güntert et al., NMR structure of the human doppel protein, Journal of Molecular Biology 326 (2003), 1549–1557.
[32] M. Lynch and S. Conery, The evolutionary fate and consequences of duplicate genes, *Science* **290** (2000), 1151–1155.

[33] E. Makrinou, J. Collinge and M. Antoniou, Genomic characterization of the human prion protein (PrP) gene locus, *Mammalian Genome* **13** (2002), 696–703.

[34] P. Mastrangelo and D. Westaway, The prion gene complex encoding PrP<sup>C</sup> and Doppel insights from mutational analysis, *Gene* **275** (2001), 1–18.

[35] A. Matsuno and T. Nagashima, Specific gene suppression using antisense strategy for growth suppression of glioma, *Medical Electron Microscopy* **37** (2004), 158–161.

[36] S. Mead, J. Beck, A. Dickinson et al., Examination of the human prion protein-like gene Doppel for genetic susceptibility to sporadic and variant Creutzfeldt–Jakob disease, *Neuroscience Letters* **290** (2000), 117–120.

[37] P.S. Mischel, T.F. Cloughesy and S.F. Nelson, DNA-microarray analysis of brain cancer: molecular classification for therapy, *Nature Review Neuroscience* **5** (2004), 782–792.

[38] R.C. Moore, I.Y. Lee, G.L. Silverman et al., Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel, *Journal of Molecular Biology* **292** (1999), 797–817.

[39] M. Nakada, S. Nakada, T. Demuth et al., Molecular targets of glioma invasion, *Cellular and Molecular Life Sciences* **64** (2007), 458–478.

[40] H. Ohgaki and P. Kleihues, Genetic pathways to primary and secondary glioblastoma, *American Journal of Pathology* **170** (2007), 1445–1453.

[41] K. Procz, C. Serres, Y. Frobert et al., The human “prion-like” protein Doppel is expressed in both Sertoli cells and spermatozoa, *Journal of Biological Chemistry* **277** (2002), 43071–43078.

[42] J. Pontén and E.H. Macintyre, Long term culture of normal and neoplastic human glia, *Acta Pathologica et Microbiologica Scandinavica* **74** (1968), 465–486.

[43] S.B. Prusiner, Novel proteinaceous infectious particles cause scrapie, *Science* **216** (1982), 136–144.

[44] D.A. Reardon, J.N. Rich, H.S. Friedman et al., Recent advances in the treatment of malignant astrocytoma, *Journal of Clinical Oncology* **24** (2006), 1253–1264.

[45] E. Sahai, Mechanisms of cancer cell invasion, *Current Opinion in Genetics & Development* **15** (2005), 87–96.

[46] S. Sathornsumetee and J.N. Rich, New treatment strategies for malignant gliomas, *Expert Review of Anticancer Therapy* **6** (2006), 1087–1104.

[47] E. Sbalchiero, A. Azzalin, S. Palumbo et al., Altered cellular distribution and sub-cellular sorting of doppel (Dpl) protein in human astrocytoma cell lines, *Cellular Oncology* **30** (2008), 337–347.

[48] D. Schechman and D. Mochly-Rosen, Adaptor proteins in protein kinase C-mediated signal transduction, *Oncogene* **20** (2001), 6339–6347.

[49] F. Shi and D. Hoekstra, Effective intracellular delivery of oligonucleotides in order to make sense of antisense, *Journal of Controlled Release* **97** (2004), 189–209.

[50] I. Tamm, Antisense therapy in malignant diseases: status quo and quo vadis?, *Clinical Science* **110** (2006), 427–442.

[51] M.A. Tranulis, A. Espenes, S. Comincini et al., The PrP-like protein doppel gene in sheep and cattle: cDNA sequence and expression, *Mammalian Genome* **12** (2001), 376–379.

[52] N.L. Tuzi, E. Gall, D. Melton et al., Expression of doppel in the CNS of mice does not modulate transmissible spongiform encephalopathy disease, *Journal of General Virology* **83** (2002), 705–711.

[53] C. Uboldi, I. Del Vecchio, M.G. Foti et al., Prion-like doppel gene (PRND) in the goat: genomic structure, cDNA, and polymorphisms, *Mammalian Genome* **16** (2005), 963–971.

[54] A. Valstar, N.L. Tran, M. Nakada et al., Cell migration and invasion assays, *Methods* **37** (2005), 208–215.

[55] M. Vicente-Manzanares, D.J. Webb and A.R. Horwitz, Cell migration at a glance, *Cell Science* **118** (2005), 4917–4919.

[56] C. Weissmann and A. Aguzzi, Perspectives: neurobiology. PrP’s double causes trouble, *Science* **286** (1999), 914–915.

[57] H. Yamaguchi, J. Wyckoff and J. Condeelis, Cell migration in tumors, *Current Opinion in Cellular Biology* **17** (2005), 559–564.